TSUBASA study: evaluation of the quality and content of daily life of people with hemophilia A without factor VIII inhibitors on prophylactic treatment with emicizumab

TSUBASA study: evaluation of the quality and content of daily life of people with hemophilia A without factor VIII inhibitors on prophylactic treatment with emicizumab

Background: Hemophilia A (HA) negatively impacts quality of life (QoL). Treatment with the bispecific antibody emicizumab has shown efficacy and safety in people with HA in clinical trials, but long-term QoL data are limited. Objectives: To investigate the QoL of people with HA receiving emicizumab...

Full description

Saved in:
Bibliographic Details
Main Authors: Teruhisa Fujii, Keiji Nogami, Akihiro Sawada, Azusa Nagao, Chiai Nagae, Masanori Nojima, Nobuaki Suzuki, Mika Kawano, Tomomi Shimura, Yoshimasa Sugao, Kagehiro Amano
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
hemophilia
emicizumab
Japan
prospective study
quality of life
Online Access:http://www.sciencedirect.com/science/article/pii/S247503792500295X
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items